Skip to content
EntityQ416361· pop 14· linked from 102 articles

Pyritinol also called pyridoxine disulfide or pyrithioxine (European drug names Encephabol, Encefabol, Cerbon 6) is a semi-synthetic water-soluble analog of vitamin B6 (Pyridoxine HCl). It was produced in 1961 by Merck Laboratories by bonding 2 vitamin B6 compounds (pyridoxine) together with a disulfide bridge. Since the 1970s, it has been a prescription and OTC drug in several countries for cognitive disorders, rheumatoid arthritis, and learning disorders in children. Since the early 1990s it has been sold as a nootropic dietary supplement in the United States.

Key facts

Drug.Verifiedfields
changed
Drug.verifiedrevid
464377508
Drug.IUPAC_name
5,5'-[dithiobis(methylene)]bis[4-(hydroxymethyl)-2-methylpyridin-3-ol]
Drug.image
Pyritinol.svg
Drug.image_class
skin-invert-image
Drug.elimination_half life
2.5 hours
Drug.CAS_number
1098-97-1
Drug.ATC_prefix
N06
Drug.ATC_suffix
BX02
Drug.PubChem
14190
Drug.ChemSpiderID
13561
Drug.UNII
AK5Q5FZH2R
Drug.KEGG
D02160
Drug.ChEMBL
488093
Drug.C
16
Drug.H
20
Drug.N
2
Drug.O
4

via Wikipedia infobox

Wikidata facts

Mass
368.086
Show 3 more facts
chemical formula
C₁₆H₂₀N₂O₄S₂
canonical SMILES
CC1=NC=C(C(=C1O)CO)CSSCC2=CN=C(C(=C2CO)O)C
Commons category
Pyritinol
Sources (4)

via Wikidata · CC0

~2 min read

Article

5 sections
Contents
  • Availability
  • Adverse effects
  • See also
  • References
  • External links

Pyritinol also called pyridoxine disulfide or pyrithioxine (European drug names Encephabol, Encefabol, Cerbon 6) is a semi-synthetic water-soluble analog of vitamin B6 (Pyridoxine HCl). It was produced in 1961 by Merck Laboratories by bonding 2 vitamin B6 compounds (pyridoxine) together with a disulfide bridge. Since the 1970s, it has been a prescription and OTC drug in several countries for cognitive disorders, rheumatoid arthritis, and learning disorders in children. Since the early 1990s it has been sold as a nootropic dietary supplement in the United States.

== Availability == It is approved for "symptomatic treatment of chronically impaired brain function in dementia syndromes" and for "supportive treatment of sequelae of craniocerebral trauma" in various European countries, including Austria, Germany, France, Italy, Portugal, and Greece. In France it is also approved for rheumatoid arthritis as a disease modifying drug, on the basis of the results of clinical trials. In many countries it is available over the counter and is widely advertised on the internet as being for "memory disturbances."

Connections

Categories